A subgroup analysis of the efficacy of filgotinib for patients with moderately active RA following an inadequate response to methotrexate

Схожі ресурси

• Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate
  за авторством: Buch, MH, та інші
  Опубліковано: (2024)
• Filgotinib modulates inflammation-associated peripheral blood protein biomarkers in adults with active rheumatoid arthritis and prior inadequate response to methotrexate
  за авторством: Tanaka, Y, та інші
  Опубліковано: (2023)
• Concomitant use of statins in filgotinib-treated patients with rheumatoid arthritis
  за авторством: Taylor, PC, та інші
  Опубліковано: (2021)
• Filgotinib, an oral JAK1 selective inhibitor with a rapid onset of action: results from the DARWIN 1 study in methotrexate inadequate response rheumatoid arthritis patients
  за авторством: Taylor, P, та інші
  Опубліковано: (2017)
• Peripheral Protein Biomarker changes following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to-severely Active Rheumatoid Arthritis with Prior Inadequate Response to Methotrexate (FINCH1)
  за авторством: Taylor, P, та інші
  Опубліковано: (2020)